# SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19)

> **NCT04738695** · — · COMPLETED · sponsor: **Sciensano** · enrollment: 3008 (actual)

## Conditions studied

- Covid19
- SARS-CoV-2 Infection

## Interventions

- **DIAGNOSTIC_TEST:** Point-of-care rapid anti-SARS-CoV-2 antibody test (Orient Gene Biotech) and Dry Blood Spot collection (Euroimmun)

## Key facts

- **NCT ID:** NCT04738695
- **Lead sponsor:** Sciensano
- **Sponsor class:** OTHER_GOV
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 3008 (ACTUAL)
- **Last updated:** 2023-11-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04738695

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04738695, "SARS-CoV-2 Seroprevalence Among Nursing Home Staff and Residents (COVID-19)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04738695. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*